97 related articles for article (PubMed ID: 233645)
1. [Role of the blood platelets in the atherosclerotic process and clinical use of a new drug, Suloctidil, with anti-aggregating activity].
Armani U; Piana A
Arch Maragliano Patol Clin; 1979; 35(2):57-62. PubMed ID: 233645
[No Abstract] [Full Text] [Related]
2. [Chronic senile cerebrovascular insufficiency. Effects of suloctidil and pentoxifylline on erythrocyte deformability].
Pilla G; Ciaponi A; Migliavacca A; Bonora C
Ric Clin Lab; 1983; 13 Suppl 3():459-64. PubMed ID: 6324325
[TBL] [Abstract][Full Text] [Related]
3. [Suloctidil (sulocton) in the treatment of atherosclerotic neurasthenic syndromes].
Prusiński A; Kotwica S; Niewodniczy A; Split W
Wiad Lek; 1982 May; 35(3-4):201-5. PubMed ID: 6287740
[No Abstract] [Full Text] [Related]
4. Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Verstraete M
Agents Actions Suppl; 1984; 15():173-87. PubMed ID: 6091423
[No Abstract] [Full Text] [Related]
5. [Effects of suloctidil therapy on platelet function in patients with on obliterating arteriopathy of the lower limbs].
Davì G; Pinto A; Novo S; Avellone G; Galati D; Mazzola A
Clin Ter; 1982 Oct; 103(2):131-7. PubMed ID: 6295693
[No Abstract] [Full Text] [Related]
6. Suloctidil: long-term trial in the aged. Study of microcirculation, viscosity, red cell deformability, fibrinolysis and lipid fractions.
Merchan R; Zurita IE; Martinez JF
Arzneimittelforschung; 1985; 35(5):855-7. PubMed ID: 2992530
[TBL] [Abstract][Full Text] [Related]
7. Effects of suloctidil on platelet survival time following cardiac valve replacement.
Col-de Beys C; Ferrant A; Moriau M
Thromb Haemost; 1981 Aug; 46(2):550-3. PubMed ID: 6272442
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
Moriau M; Col-De Beys C; Pardonge E; Ferrant A
Thromb Haemost; 1982 Feb; 47(1):27-31. PubMed ID: 6280332
[TBL] [Abstract][Full Text] [Related]
9. [Hemorrheological survey in a group with arteriosclerotic vascular disease treated with suloctidil].
Caimi G; Catania A; Frazzetta F; Capobianco D; Francavilla G; Romano A; Sarno A
Ric Clin Lab; 1983; 13 Suppl 3():465-8. PubMed ID: 6324326
[TBL] [Abstract][Full Text] [Related]
10. In vivo effect of suloctidil as an antiplatelet agent.
Stelzer MR; Burns TS; Saunders RN
Thromb Haemost; 1979 May; 41(3):465-74. PubMed ID: 462414
[TBL] [Abstract][Full Text] [Related]
11. [Medium term treatment with suloctidil in obliterating arteriopathies of the lower limbs. Personal experience].
Marongiu G; Dettori G; Gadeddu A; Noya G; Angius P; Biglioli P
Minerva Cardioangiol; 1983; 31(7-8):407-10. PubMed ID: 6316206
[No Abstract] [Full Text] [Related]
12. Activation of platelets and of fibrinolysis by venous occlusion in healthy volunteers and influence of suloctidil in comparison with placebo.
Baele G; Bary JL; van Stalle F
Arzneimittelforschung; 1983; 33(8):1203-5. PubMed ID: 6315025
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic use of a new vasoactive drug in cerebral vascular diseases in elderly patients].
Petronio G; Scali G; Casa B; Nonis E
Clin Ter; 1980 Aug; 94(4):427-44. PubMed ID: 6257445
[No Abstract] [Full Text] [Related]
14. [Suloctidil in the treatment of focal cerebral ischemia].
Bartko D; Zúzi M; Brezná M; Trávniková M; Porubec V
Cesk Neurol Neurochir; 1984 Mar; 47(2):103-8. PubMed ID: 6323038
[No Abstract] [Full Text] [Related]
15. [Further observations on the use of Suloctidil (Sulocton) in the treatment of migraine].
Prusiński A; Durko A; Głuszcz-Zielińska A; Szymańska R
Wiad Lek; 1984 Dec; 37(23):1857-9. PubMed ID: 6099634
[No Abstract] [Full Text] [Related]
16. Studies of suloctidil in experimental thrombosis in baboons.
Hanson SR; Harker LA
Thromb Haemost; 1985 Jun; 53(3):423-7. PubMed ID: 2996168
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients.
Roncucci R; De Hertogh R; Dormandy JA; Doumont J; Gurewich V; Lambelin G; Lansen J; Rottiers R; Souridis E; Van Stalle F; Versee L
Arzneimittelforschung; 1979; 29(4):682-4. PubMed ID: 582768
[TBL] [Abstract][Full Text] [Related]
18. [Clinical trial of suloctidil (sulocton) for the treatment of migraine (preliminary report)].
Prusiński A
Neurol Neurochir Pol; 1981; 15(3):309-11. PubMed ID: 6273762
[TBL] [Abstract][Full Text] [Related]
19. Effect of suloctidil on platelet function in patients with shortened platelet survival time.
Turpie AG; Gent M; deBoer AC; Giroux M; Kinch D; Butt R; Gunstensen J; Saerens E; Genton E
Thromb Res; 1984 Aug; 35(4):397-406. PubMed ID: 6091290
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of sulocton action in patients with atherosclerotic brain ischemia].
Karwowski B; Jura E; Krasicka J; Kruszewska J; Laskowska-Studniarska W; Szymchel J; Nielubowiczowa H
Neurol Neurochir Pol; 1982; 16(4):237-43. PubMed ID: 6292759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
